The Latest Breaking News from DHR

Danaher has underperformed the Medical Devices industry, though Wall Street analysts remain strongly optimistic about its future prospects.

Although Danaher has underperformed relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

The healthcare industry is poised for tremendous growth driven by the aging population and rising incidence of chronic diseases. Hence, quality healthcare stocks, Danaher (DHR), Amgen (AMGN), and DexCom (DXCM), benefiting from an aging population, might be worth looking into. Read more….

Indian medical institutions aim to improve research quality and global rankings, focusing on impactful solutions for citizens' problems.

In the specialized field of spinoff companies, Veralto emerges as a prime investment opportunity, stemming from its recent spinoff from Danaher Corporation.

With rapidly increasing healthcare demands, numerous technological breakthroughs, and advanced research and development, the medical industry is well-poised for remarkable growth and profitability. As medical companies Danaher (DHR) and Stryker (SYK) gear to report their fourth-quarter earnings tomorrow, let’s determine if these stocks are ideal buys ahead of earnings….

Danaher Corp, the biotech/life sciences products firm, has had unusual call options activity today. It highlights the value of shorting out-of-the-money "covered calls" in DHR stock as an income play.

Spinoffs and Parents in these sectors do well. 23 years of data from says that Large-cap Parents and Spinoffs within the Healthcare and Industrials sector observe a consistent trend of outperformance. This suggests that investors could see a similar trend with DHR and VLTO post-Spin.

Start looking for CEOs who say their business is bottoming out.